Tag:
ridaforolimus
Latest Headlines
Latest Headlines
FDA questions benefit of Merck and Ariad’s bone cancer drug
Merck ( $MRK ) and Ariad Pharmaceuticals ( $ARIA ) face a big test for their experimental cancer drug ridaforolimus next week. In briefing docs released today, FDA staffers questioned whether the drug should be approved given the slim survival benefits that it provides. That will be a central question for FDA advisers to consider at an advisory committee meeting slated for March 20.
FDA opts for standard review on bone cancer drug from Ariad, Merck
Much as was expected, the FDA accepted the NDA from Ariad Pharmaceuticals and Merck on their closely watched cancer drug ridaforolimus. But there was more than one eyebrow raised by the agency's
Ariad snags $25M milestone from Merck as ridaforolimus advances
Ariad is pocketing a $25 million milestone from Merck, qualifying for the payout as their partnered cancer drug, ridaforolimus, advances along the regulatory path. Merck is handing over the money
Ariad boosted by news of Merck's application for ridaforolimus
Shares of Ariad Pharmaceuticals ( $ARIA ) got a boost this morning as its development partner Merck ( $MRK ) took one more big step forward in its quest for an approval of ridaforolimus . The Big Pharma
UPDATED: ASCO roundup: Fresh progress of Merck, Pfizer cancer drugs
The burst of cancer drug news out of ASCO has spotlighted significant advances on a host of new drug programs, with Merck and Pfizer both benefiting from the limelight. (You can find fresh data on
Ariad shares soar after cancer drug clears late-stage trial hurdle
Eight months after Merck ( $MRK ) jumped into the driver's seat to take control of Ariad's late-stage cancer program ridaforolimus, the biotech is reporting that one of its Phase III study turned in
TheStreet tracks the top 10 clinical trials to watch
TheStreet's top biotech stock ace, Adam Feuerstein, has culled through a mountain of releases and reports to come up with the 10 most closely-watched trial announcements expected in the second half
